1. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents. (9th November 2020) Authors: Bernett, Matthew; Varma, Rajat; Liu, Ke; Bonzon, Christine; Rashid, Rumana; Rodriguez, Nicole; Hassanzadeh-Kiabi, Nargess; Ardila, Connie; Chu, Seung; Muchhal, Umesh; Desjarlais, John Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A340 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents. (9th November 2020) Authors: Bernett, Matthew; Varma, Rajat; Liu, Ke; Bonzon, Christine; Rashid, Rumana; Rodriguez, Nicole; Hassanzadeh-Kiabi, Nargess; Ardila, Connie; Chu, Seung; Muchhal, Umesh; Desjarlais, John Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A598 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells. (9th November 2020) Authors: Li, Cong; Fort, Madeline; Liang, Lingming; Moore, Gregory; Bernett, Matthew; Muchhal, Umesh; Osgood, Tao; Yabut, Rodolfo; Kaliyaperumal, Sarav; Harrold, John; Canon, Jude; Rogojina, Anna; Kurmasheva, Raushan; Desjarlais, John; Houghton, Peter; Nolan-Stevaux, Olivier Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A430 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells. (9th November 2020) Authors: Li, Cong; Fort, Madeline; Liang, Lingming; Moore, Gregory; Bernett, Matthew; Muchhal, Umesh; Osgood, Tao; Yabut, Rodolfo; Kaliyaperumal, Sarav; Harrold, John; Canon, Jude; Rogojina, Anna; Kurmasheva, Raushan; Desjarlais, John; Houghton, Peter; Nolan-Stevaux, Olivier Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗